Standard Biotools (LAB) Leases (2019 - 2026)

Standard Biotools (LAB) has 8 years of Leases data on file, last reported at $25.5 million in Q1 2026.

• Quarterly Leases fell 6.84% year-over-year to $25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.5 million (down 6.84% YoY) and the FY2025 annual result came in at $26.7 million, up 0.62% from the prior year.
• Leases retreated to $25.5 million in Q1 2026 per LAB's latest filing, from $26.7 million in the prior quarter.
• Across five years, Leases topped out at $36.4 million in Q1 2022 and bottomed at $23.5 million in Q3 2025.
• The 5-year median for Leases is $31.2 million (2023), against an average of $30.4 million.
• Peak annual rise in Leases reached 0.62% in 2025, while the deepest fall reached 22.51% in 2025.
• Tracing LAB's Leases over 5 years: stood at $33.9 million in 2022, then declined by 9.5% to $30.7 million in 2023, then decreased by 13.36% to $26.6 million in 2024, then climbed by 0.62% to $26.7 million in 2025, then slipped by 4.44% to $25.5 million in 2026.
• Per Business Quant, the three latest LAB Leases figures stand at $25.5 million (Q1 2026), $26.7 million (Q4 2025), and $23.5 million (Q3 2025).

Peer Comparison